News
Eli Lilly and Company's stock dropped 11% after CVS's Zepbound exclusion, but analysts see a mispricing opportunity. Click ...
CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...
Looking for undervalued stocks? Check out three top undervalued stocks to buy now in May, 2025 to boost your portfolio.
Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of ...
StockStory.org on MSN16h
LLY Q1 Earnings Call: Revenue Beats Expectations, Profit Guidance Trimmed Amid Price PressuresGlobal pharmaceutical company Eli Lilly (NYSE:LLY) reported in Q1 CY2025, with sales up 45.2% year on year to $12.73 billion.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback